LON:SSIT

LON:SSIT - Seraphim Space Investment Trust PLC

OPPORTUNISTIC BUY [CAP] BUY?OPPORTUNISTIC BUYFinancial Services - Asset ManagementAnalysis generated 2026-10-04Market data as of 2026-11-13Market data 2 days old177.25p

Conviction

out of 100

Executive Summary

Seraphim Space (SSIT) is principally a private-company valuation and liquidity case. Its October factsheet's observation date is 30 June, when ordinary NAV was 240.49p and ICEYE represented 53.9% of total NAV. ICEYE's financing-round valuation is not evidence of cash proceeds to SSIT. These are dated valuation marks, not a live November NAV or current premium/discount. ([Issuer June-quarter factsheet, published October](https://investors.seraphim.vc/wp-content/uploads/2026/10/Q4-FY25_26-SSIT-NAV-Factsheet-FINAL.pdf)) The AGM circular reports 228% average annual revenue growth across its top ten holdings; expected EBITDA profitability by end-2026 remains a forecast. Next check: subsequent NAV, ICEYE concentration, liquidity and whether portfolio funding/profitability expectations materialise. FTSE 250 admission on 19 June is confirmed. ([October AGM circular](https://investors.seraphim.vc/wp-content/uploads/2026/10/Seraphim-Notice-of-AGM-Circular-v.Final_.pdf); [index admission announcement](https://www.londonstockexchange.com/news-article/SSIT/admission-to-the-ftse-250-index/17627354))

Business Model

Seraphim Space is a closed-end investor in mainly private space and related technology companies. Shareholder returns depend on portfolio valuations, realised exits, funding and currency movements rather than an operating-company earnings multiple. At 30 June 2026 ICEYE represented 53.9% of total NAV, making the exposure materially concentrated despite holding multiple companies.

Financial Snapshot

Price

177.25p

P/E Ratio

2.3x

52w High

284.00p

52w Low

75.00p

Distance from 52wH

-37.6%

Avg Volume

1024749

Currency

GBX

Recent Catalysts

[October 2026 publication; 30 June observation date] Issuer factsheet reported ordinary NAV 240.49p and ICEYE at 53.9% of total NAV. Financing-round marks are not cash proceeds to the trust. [October AGM circular] Top-ten average annual revenue growth was 228%; this is not earnings growth. Expected end-2026 EBITDA profitability remained a management forecast. [19 June 2026] FTSE 250 admission occurred.

Thesis Evaluation

Bull Case (47% weight)

Portfolio growth leads to funded businesses and realised exits that substantiate valuation marks.

Base Case (48% weight)

Reported NAV remains sensitive to private funding rounds, concentration and FX while exits are intermittent.

Bear Case (5% weight)

Down rounds, financing needs or premium compression reduce shareholder returns despite reported portfolio growth. Previously published numerical target references, retained without revaluation in this factual correction: 270p, 220p, 110p. See the unchanged entry framework. These levels were not revalidated by this review.

Weighted conviction:Bull (47%) x 100 + Base (48%) x 62 + Bear (5%) x 10 = 64/100. OPPORTUNISTIC BUY.

Key Risks

ICEYE concentration: ICEYE was 53.9% of total NAV at 30 June. This is a dated observation, not a November allocation.
Valuation and liquidity: Private funding-round marks and revenue growth do not establish earnings or realised cash returns.
FX and premium/discount: Currency movements and changes in the share-price relationship to NAV can affect returns. No live November NAV or premium was verified.

Who Should Own It / Avoid It

Ideal for: long-term growth-oriented investors with a multi-year horizon (minimum three to five years), a high tolerance for mark-to-market volatility in unlisted equity holdings, and a thesis on the structural growth of SpaceTech and defence spending. The trust is appropriate for investors who understand closed-end fund dynamics, including the potential for the premium to NAV to compress, and who are comfortable with FX-driven reported-return variability.

Avoid if: investors require short-term liquidity, cannot tolerate double-digit drawdowns driven by FX or sentiment swings, or need a current-income yield rather than capital appreciation. Conservative capital-preservation profiles, investors with a benchmark to broad equity index returns over a one- to two-year window, and those unwilling to accept the lumpy realisation profile typical of unlisted SpaceTech holdings should look elsewhere.

Recommendation

OPPORTUNISTIC BUY - 64/100. The published model score and recommendation are retained from the prior calculation, not reassessed by this factual correction. Reported NAV remains sensitive to private funding rounds, concentration and FX while exits are intermittent. Review the dated disclosures and remaining risks before using the existing model output.

The probability-weighted value across our three scenarios is 238.00p, 33% above the current price of 178.60p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.

BUY

below 146.67p - below this level the upside to the base-case target (220.00p) is at least 2x the downside to the bear case (110.00p), the minimum risk/reward we require before committing new capital.

HOLD

between 146.67p and 220.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.

REDUCE

above 220.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 47%.

SELL

if A sustained reversal of portfolio valuation gains (portfolio fair value falling back towards cost), a material crystallisation of disclosed FX losses that meaningfully reduces reported NAV, or the loss of FTSE 250 index status would invalidate the thesis regardless of price, regardless of price - the bear target of 110.00p is the backstop, not an arbitrary percentage stop.

Conviction Trend

Latest conviction: 64/100. Trend versus prior report: Flat.

CONVICTION BUY (80+)BUY (65 - 79)OPP BUY (50 - 64)SPEC BUY (30 - 49)AVOID (0 - 29)

Report date	Conviction
2026-11-14	64
2026-10-04	64

See the trade-card view →

Sources

Factual correction checked 14 November 2026. [Issuer June-quarter factsheet, published October](https://investors.seraphim.vc/wp-content/uploads/2026/10/Q4-FY25_26-SSIT-NAV-Factsheet-FINAL.pdf) [October AGM circular](https://investors.seraphim.vc/wp-content/uploads/2026/10/Seraphim-Notice-of-AGM-Circular-v.Final_.pdf) [index admission announcement](https://www.londonstockexchange.com/news-article/SSIT/admission-to-the-ftse-250-index/17627354) Remaining gaps and date qualifications are retained in the narrative. Numerical model outputs and entry levels were not recalculated.

Key sources

Analysis generated 2026-10-04. Market data as of 2026-11-13.